Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 1;26(4):tay138.
doi: 10.1093/jtm/tay138.

Safety of atovaquone-proguanil during pregnancy

Romana C Mayer  1 , Kathrine R Tan  2 , Julie R Gutman  2
Affiliations

Safety of atovaquone-proguanil during pregnancy

Romana C Mayer et al. J Travel Med. .

Abstract

Background: Malaria during pregnancy increases the risk of maternal and foetal complications. There are very limited options for prophylaxis in pregnant travellers. Atovaquone-Proguanil (AP or Malarone®) is an effective and well-tolerated antimalarial medication, but is not recommended for use in pregnancy due to limited data on safety. Passively reported adverse event data may provide additional information on the safety of AP during pregnancy.

Methods: We analysed adverse event data on pregnancy and birth outcomes following accidental exposures to AP during pregnancy, which were passively reported to GlaxoSmithKline LLC (GSK) between 13 May 1997 and 15 August 2017. Birth outcomes of interest included live birth, miscarriage, and stillbirth. Adverse outcomes of interest were defined as any of the following: small for gestational age (SGA), low birth weight (LBW, <2500 gm), congenital anomalies, and a composite 'poor live birth outcome,' including preterm birth (PTB), LBW or SGA.

Results: Among 198 women who received AP during pregnancy or breastfeeding, 96.5% occurred in women taking malaria prophylaxis, and 79.8% of exposures occurred in the first trimester. Among 195 with available birth outcome data, 18.5% resulted in miscarriage and 11.8% were elective terminations. Available adverse outcomes included SGA in 3.5% (3/85), LBW in 7.0% of infants (6/86), and the composite 'poor live birth outcome' in 13.7% (14/102). Congenital anomalies were reported in 30/124 (24.2%), with no specific pattern to suggest an effect related to AP.

Conclusions: These data provide a description of outcomes in the pregnancies reported to this dataset, and it should be noted that there is likely a bias towards reporting cases resulting in poor outcomes. While there was no specific signal to suggest a teratogenic effect of AP, AP data during pregnancy were too limited to determine AP's safety with confidence. As inadvertent exposures are not infrequent, better data are needed.

Keywords: Atovaquone; malaria; pregnancy; proguanil; safety.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have no conflicts of interest to report. The authors had full control of the data and the decision to publish.

References

    1. Desai M, ter Kuile FO, Nosten F et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007; 7:93–104. - PubMed
    1. CDC Health Information for International Travel 2016. Centers for Disease Control and Prevention, Brunette Gary W. (Ed.-in-Chief), Kozarsky Phyllis E. (Chief Med. Ed.), Cohen Nicole J., Gershman Mark D., Magill Alan J., Ostroff Stephen M., Ryan Edward T., Shlim David R., Weinberg Michelle, and Wilson Mary Elizabeth (Med. Eds.). New York, NY: Oxford University Press, 2016. 688pp.
    1. Looareesuwan S, Viravan C, Webster HK et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in thailand. Am J Trop Med Hyg 1996; 54:62–6. - PubMed
    1. Food and Drug Administration. Malarone prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21078se5-006_m... (13 September 2018, date last accessed).
    1. Ward SA, Sevene EJ, Hastings IM et al. Antimalarial drugs and pregnancy: Safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 2007; 7:136–44. - PubMed

MeSH terms